



September 2023

Dear BCAN Board of Directors,

As a valued partner in healthcare, we want to keep you informed of our commitment to **TICE® BCG BCG LIVE** (for intravesical use) ("TICE BCG"). As you may know, in 2012, Merck unexpectedly became the sole supplier of TICE BCG in many countries around the world, including the United States. Prior to 2012, Merck supplied 25% to 30% of the US market. Unfortunately, increasing demand has outpaced our current maximum manufacturing capabilities. In recognition of the impact that supply shortages can have on patients, our company took steps to increase production of TICE BCG by **more than 200 percent**, between 2012 and 2019, and we continue to operate at **maximum production capacity**.

In October 2020, Merck announced plans to **construct a new manufacturing facility**, investing several hundred million dollars, to significantly expand production capacity for TICE BCG. Once fully operational, we expect to **triple the current manufacturing capacity** to support the anticipated demand for TICE BCG for the foreseeable future. Construction is well underway and barring any unforeseen circumstances, we believe we will be able to begin production of TICE BCG at the new facility between late 2025 and late 2026.

The photo shows the progress made on the new manufacturing facility in Durham, NC (June 2023).



In addition, in the United States, we continue to supply TICE BCG consistently to our network of distributors and wholesalers. The wholesalers and distributors in turn allocate TICE BCG to their healthcare professional customers.

Merck remains **committed to increasing the global supply of TICE BCG** and is continuously evaluating ways to increase production in our current facility until our new facility is fully operational.

We hope this update was informative and allows you to understand the work that has been taking place. If you have additional questions, you may refer to our **TICE BCG frequently asked questions** on Merck.com, or contact the Merck National Service Center at **800-NSC-MERCK** (800-672-6372).

Regards,

A handwritten signature in black ink that reads "Jannie Oosthuizen".

Jannie Oosthuizen
President, Human Health US

A handwritten signature in black ink that reads "John McGrath".

John McGrath
Sr. Vice President, Global Vaccine Operations